Literature Review: Moving the Druggable Needle
The Use of an mRNA Display Technology and Affinity-Based Selection Is Used to Find Inhibitors to an Enzyme of Interest
To Surge or Not to Surge?
Experts Discuss Inclusion of a Surge Tank in an End-to-End Continuous Biomanufacturing Train
New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
- 8405 Helgerman Ct
- Gaithersburg MD, 20877
- UNITED STATES
Trevigen Cell Assays (TCA), a division of Trevigen, Inc., was established in 2008 to conduct contract research work for the pharmaceutical, biotechnology, government and academic segments of the medical research market. TCA specializes in designing and conducting assays for lead compounds and genotoxic screening based on DNA damage and repair as well as cancer cell behavior.